J. Ajani

Abstract A040: Intratumor stem cell repertoire in pancreatic cancer

Metastatic pancreatic ductal adenocarcinoma (PDAC) is difficult to manage, has an overall survival of approximately nine months, and will soon be the second leading cause of death among cancers. The poor outcome of PDAC patients has been attributed, in part, to a pattern of intratumor heterogeneity reflected in the g...

Automated detection of gastroesophageal adenocarcinoma recurrence from electronic health records.

Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States

Abstract Background Contemporary real-world evidence in advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC) remains limited. This study evaluated real-world treatment patterns and clinical outcomes in patients with advanced GC/GEJC/EAC treated with first-line therapy in the United St...

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

BACKGROUND Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....

Abstract A017: FAP-Activated Prodrugs Target Cancer Stem Cells in Esophageal Adenocarcinoma

FAP-activated ponatinib prodrugs achieve selective, TME-compartmentalized delivery with substantially reduced systemic exposure and, when combined with the IAP antagonist 7532N as the TP101 regimen, provide a precision, stem cell-selective synthetic lethal strategy for this rare and aggressive malignancy.

Pharmacologic Inhibition of SOX9-CDK4 by CYD-4-61 Impairs Gastric Adenocarcinoma Growth and Amplifies Anti-PD-1 Response.

Findings identify the BAX-SOX9-CDK4 axis as an important mechanism contributing to the antitumor activity of CYD-4-61 and provide a strong preclinical rationale for its further development as a therapeutic strategy for aggressive GAC.

Abstract B039: Genomic and epigenomic complexity underlies barrett’s esophagus progression to adenocarcinoma

This study defines the role of epigenetic reprogramming in BE-to-EAC progression by integrating spatial transcriptomics, single-cell analyses, and functional modeling, and demonstrates that enhancer activation correlates with transitions from stable epithelial identity to highly plastic, dysplastic, and malignant pheno...